Disc Medicine (NASDAQ:IRON) Insider William Jacob Savage Sells 13,093 Shares

Disc Medicine, Inc. (NASDAQ:IRON) insider William Jacob Savage sold 13,093 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $91.22, for a total transaction of $1,194,343.46. Following the completion of the sale, the insider owned 75,702 shares in the company, valued at $6,905,536.44. This represents a 14.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Disc Medicine Stock Down 0.6%

Shares of NASDAQ IRON traded down $0.53 during trading hours on Tuesday, hitting $91.47. 639,414 shares of the stock were exchanged, compared to its average volume of 536,679. Disc Medicine, Inc. has a 12 month low of $30.82 and a 12 month high of $99.50. The firm has a fifty day moving average price of $86.99 and a 200-day moving average price of $68.22. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05. The company has a market cap of $3.45 billion, a PE ratio of -17.10 and a beta of 0.87.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.29). On average, sell-side analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on IRON. Morgan Stanley boosted their target price on Disc Medicine from $90.00 to $115.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Stifel Nicolaus initiated coverage on Disc Medicine in a report on Monday, November 3rd. They issued a “buy” rating and a $125.00 price target for the company. National Bankshares set a $153.00 price objective on shares of Disc Medicine in a report on Friday, October 17th. Cantor Fitzgerald lifted their target price on shares of Disc Medicine from $132.00 to $153.00 and gave the stock an “overweight” rating in a research note on Friday, October 17th. Finally, Wedbush boosted their target price on shares of Disc Medicine from $90.00 to $110.00 and gave the stock an “outperform” rating in a research report on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $119.00.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Aster Capital Management DIFC Ltd acquired a new stake in shares of Disc Medicine during the 3rd quarter worth approximately $38,000. CWM LLC boosted its holdings in Disc Medicine by 213.5% during the second quarter. CWM LLC now owns 1,044 shares of the company’s stock worth $55,000 after buying an additional 711 shares in the last quarter. Avanza Fonder AB acquired a new stake in Disc Medicine during the second quarter valued at $57,000. Mirae Asset Global Investments Co. Ltd. grew its position in Disc Medicine by 15.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company’s stock valued at $71,000 after buying an additional 181 shares during the period. Finally, Ameritas Investment Partners Inc. increased its holdings in Disc Medicine by 8.9% in the second quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock valued at $133,000 after buying an additional 206 shares in the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.